Georges holds a Ph.D. in microbiology from the University of Paris VI and a business & management training from the ESSEC Business School. For more than 25 years, he has worked at different positions in the pharma/biotech industry as scientist, drug discovery professional, business development expert and entrepreneur supporting biotechnology companies building their pipeline and strategy at the forefront of modern science. He is currently serving as board member of different biotechs, including Alia Therapeutics and Apmonia, and as Chief Biotech Studio at the investment firm eureKARE.  Georges was CEO of YSOPIA Bioscience. Prior to this, he was BD & Intellectual Property VP and member of Celyad management team. He successfully held various senior BD positions at Cellectis, Galapagos, ProStrakan and Sanofi-Aventis and led strategic alliance consulting assignments.